Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.
JH
Lipton
;
P
Bryden
;
MK
Sidhu
;
H
Huang
;
LJ
McGarry
;
S
Lustgarten
;
S
Mealing
;
B
Woods
;
J
Whelan
;
N
Hawkins
;
(2014)
Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.
Leukemia research, 39 (1).
pp. 58-64.
ISSN 0145-2126
DOI: 10.1016/j.leukres.2014.10.005
We compared the efficacy of ponatinib and second-generation tyrosine kinase inhibitors (2G-TKIs: bosutinib, dasatinib, and nilotinib) in chronic phase CML resistant/intolerant to ≥1 prior 2G-TKI. Estimated probabilities of CCyR with 2G-TKI ranged from 22% to 26%, compared with 60% (95% CrI 52-68%) with ponatinib. The estimated probability of ponatinib providing higher response rate than all other included treatments was 99% (CCyR) and 97% (MCyR). Use of further 2G-TKI may provide limited benefit in CP-CML patients resistant/intolerant to prior 2G-TKI treatment. Compared with 2G-TKIs, ponatinib is estimated to provide substantially higher probability of achieving CCyR and MCyR; safety was not compared.
| Item Type | Article |
|---|---|
| Keywords | Disease-Free Survival, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelogenous, Chronic, BCR-ABL Positive:, Protein Kinase Inhibitors, Protein Kinase Inhibitors: adverse effects, Protein Kinase Inhibitors: therapeutic use, Survival Rate, Disease-Free Survival, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, mortality, Protein Kinase Inhibitors, adverse effects, therapeutic use, Survival Rate |
| ISI | 346858200009 |
| Date Deposited | 10 Mar 2016 20:17 |